高危胃癌术前序贯化疗联合放化疗的II期试验
39例完成序贯治疗,33例实现R0切除,其中病理缓解率为39.4%,3年总生存率在0-I期、II-III期及不可切除患者中分别为77.9%、66.8%和33.3%(P=0.001)。毒性以轻至中度为主。
要点
- 术前序贯化疗联合放化疗在高危胃癌中可行且有效
- 33例R0切除患者病理缓解率为39.4%
- 3年总生存率随分期升高而降低,不可切除者最差
核心结论
- 术前序贯化疗后同步放化疗对高危胃癌可行且有效。
主要发现
- 33例R0切除患者病理缓解率为39.4%,其中无残留癌5例(15.2%)、残留癌1-10%者8例(24.2%)。
- 病理分期0期4例(12.1%)、I期7例(21.2%)、II期10例(30.3%)、III期12例(36.4%)。
- 3年总生存率:0-I期77.9%,II-III期66.8%,不可切除者33.3%(P=0.001)。
- 毒性以轻至中度为主,最突出为4级中性粒细胞减少1例和中性粒细胞减少性发热1例。
关键数值与推荐
- 纳入标准:Borrmann 4型;大型Borrmann 3型(≥8 cm);单个巨大淋巴结(≥3 cm×1)或多个淋巴结(≥1.5 cm×3)。
- 诱导化疗方案:TS-1 35 mg/m2口服每日两次第1-14天,多西他赛30 mg/m2静注第1、8天,顺铂30 mg/m2静注第1、8天,每21天为一周期,共两周期。
- 同步放化疗方案:两周期TS-1联合顺铂同步45 Gy放疗。
临床怎么用
- 对符合高危标准(Borrmann 4型、大型Borrmann 3型或淋巴结转移符合条件)的胃癌患者,可考虑术前序贯化疗后同步放化疗再手术的治疗策略。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the safety and efficacy of preoperative chemotherapy (CTx) followed by chemoradiotherapy (CCRT) for high-risk gastric cancer (GC). METHODS AND MATERIALS: The inclusion criteria were as follows: (1) Borrmann type 4; (2) large Borrmann type 3 (≥8 cm); (3) single bulky (≥3 cm × 1) or multiple lymph nodes (≥1.5 cm × 3). Patients received two 21-day courses of induction CTx of TS-1 (35 mg/m2, p.o, twice daily on days 1-14), docetaxel (30 mg/m2, i.v., days 1 and 8), and cisplatin (30 mg/m2, i.v., days 1 and 8) followed by CCRT (two courses of TS-1 and cisplatin in combination with 45 Gy radiation). RESULTS: Forty-two patients were enrolled between March 2014 and February 2016, and 39 of these completed sequential CTx and CCRT. Among the 33 patients who underwent R0 resection, the pathologic response rate was 39.4% [no residual carcinoma (n = 5, 15.2%), with 1-10% residual carcinoma (n = 8, 24.2%)]. Overall, 4 patients (12.1%) were pathologic stage 0, 7 (21.2%) were stage I, 10 (30.3%) were stage II, and 12 (36.4%) were stage III. The overall survival rate at 3 years was 77.9% for stages 0 and I, 66.8% for stages II-III, and 33.3% for unresectable cases (P = 0.001). Toxicity was mild to moderate with grade 4 neutropenia (n = 1) and neutropenic fever (n = 1) as the most prominent side-effects. CONCLUSIONS: Sequential CTx and CCRT prior to surgery are feasible and effective for high-risk GC. TRIAL REGISTRATION NUMBER: NCT02495493.
引用
- Kim HS, Koom WS, Baek SE, et al. Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. Radiother Oncol. 2019. PMID: 31302344. doi:10.1016/j.radonc.2019.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。